LimmaTech Biologics AG Employee Directory
Biotechnology ResearchZurich, Switzerland51-200 Employees
LimmaTech Biologics AG is a Swiss clinical-stage biopharmaceutical company focused on preventing infectious diseases through vaccines. It pursues its own proprietary vaccine candidates and also develops vaccines in collaboration with GSK. The company operates from Schlieren, near Zurich, Switzerland, and is part of the biotechnology research sector. Its portfolio targets bacterial pathogens with increasing antimicrobial resistance, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis, as well as Shigella through the S4V2 program. In 2025, the company announced a collaboration with Valneva to advance the S4V2 Shigella vaccine. The organization is mid-sized and concentrates on infectious disease prevention within the biotech research field.